About Dr. Daniel Tang

Dr. Daniel Tang is the Chief Operating Officer (COO) and Executive Vice President (EVP) of Phanes Therapeutics, Inc. He is a seasoned executive with significant experience in the Pharmaceutical, Biotech and Contract Research Organization (CRO) industries. In the past 20 years, Daniel has developed unique skill sets in drug research & development, general management and business development both in Asia and USA.


Previously Daniel was CEO and board member of United Power PharmaTech (UPP) in Beijing, China. In this role, he took the lead to develop UPP as one of the largest biologics development CROs in Asia. Prior to joining UPP, Daniel was General Manager of ICON Development Solutions in APAC, responsible for ICON’s overall business for lab services and early clinical trials. Before ICON, he was Vice President of Bioanalysis and DMPK of Frontage (China) Laboratories and Vice President of ChemPartner. Daniel also worked for QPS, Pfizer and DuPont with increasing scientific and managerial responsibilities.


Daniel has authored or co-authored over 30 research/conference papers and is a frequent speaker in international conferences. Daniel has been actively participating in the efforts of global harmonization on bioanalytical guidelines. He is one of the authors for the AAPS white paper on Incurred Sample Reanalysis (ISR), which became one key requirement in EMA/FDA/China Pharmacopeia Bioanalytical Method Validation guidance and industrial practice. He is a steering committee member in Global Bioanalysis Consortium (GBC), a global non-profit scientific organization with the aim to harmonize bioanalytical guidance across different regions around the world. He co-founded and led China Bioanalysis Forum (CBF), the first bioanalysis focused organization in China, and led the effort to draft the first bioanalytical method validation (BMV) guidance for China Pharmacopeia. Daniel also chaired the Special Interest Group (SIG) of Analytical Science and Pharmaceutical Quality (ASPQ) in International Pharmaceutical Federation (FIP).


Daniel obtained his BS in Biochemistry from Peking University, PhD in Chemistry from the George Washington University and MBA from the University of Michigan.